Skip to main content
. 2017 Dec 7;39(3):393–404. doi: 10.1038/aps.2017.161

Figure 3.

Figure 3

ASA VI enhanced migration and tube formation of HUVECs. (A) Transwell migration assay results of HUVECs with different treatments. HUVECs were treated with PBS (control), 50 ng/mL bFGF and 20, 40, and 80 μg/mL ASA VI in the lower chamber for 3 h incubation. The migration of HUVECs was enhanced after ASA VI treatment (scale bar: 50 μm). (B) In vitro tube formation results of HUVECs treated by ASA VI. The tube formation ability of HUVECs was improved after ASA VI treatment (scale bar: 200 μm). n=3 independent experiments. *P<0.05, **P<0.01.